NEW YORK and CALGARY, Sep 10, 2015 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that Mr. Donald McCaffrey, president and chief executive officer of Resverlogix Corp. will be presenting today at the Rodman & Renshaw 17th Annual Global Investment Conference at 10:25 am EDT in Louis XVI A (2nd floor, St. Regis Hotel, New York). The presentation will be available via webcast at: http://wsw.com/webcast/rrshq25/rvxhttp://wsw.com/webcast/rrshq25/rvx
About RVX-208 (apabetalone)
RVX-208 "apabetalone," is a first-in-class, small molecule selective BET bromodomain inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can turn disease-causing genes off, returning them to a healthier state. RVX-208 is the first and only BET inhibitor selective for BRD4-BD2, producing a nexus of biological effects with potentially important benefits for patients with diseases such as cardiovascular disease (CVD), diabetes mellitus (DM), Alzheimer's disease, peripheral artery disease, and chronic kidney disease while maintaining an excellent safety profile. Resverlogix's Phase 3 trial BETonMACE in CVD patients with DM and low HDL is planned to commence in the fall of 2015.
Resverlogix Corp. is developing RVX-208, a first-in-class, small molecule selective BET bromodomain inhibitor for the potential treatment of patients with cardiovascular disease, diabetes mellitus, Alzheimer's disease, peripheral artery disease, and chronic kidney disease. RVX-208 is the only selective BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog and via Twitter @Resverlogix_RVX https://twitter.com/resverlogix_rvx.
Donald J. McCaffrey
President and CEO
Director, Investor Relations & Corporate Communications
SOURCE Resverlogix Corp.